Smith+Nephew reports director's shareholding
A PDMR transaction has been disclosed in compliance with regulations.
See the latest news and media coverage for Smith+Nephew. We track all announcements, press releases, and industry mentions in real time, all in one place.
Portfolio medical technology company for tissue repair and replacement
smith-nephew.comLast updated
In short: Smith+Nephew reported strong 2025 financial growth and launched its RISE strategy to target 6-7% revenue growth and high cash flow through 2028.
A PDMR transaction has been disclosed in compliance with regulations.
It shows growth across all units and regions, innovation-driven growth, unchanged guidance, and $500 million share buyback.
The China facility receives recognition for operational excellence.
Invests $296m in innovation. Shares 170-year history and new RISE strategy in annual report.
Smith & Nephew stock is underpinned by a solid first-quarter 2026 trading update and a new $500 million share buyback. Growth was led by Sports...
Detailed price information for Smith & Nephew Snats ADR (SNN-N) from The Globe and Mail including charting and trades.
Smith & Nephew PLC (LSE:SN) efforts to expand its surgical robotics platform and strengthen its orthopaedics pipeline received a vote of confidence from surgeons at...
Subsequent changes in holdings or intentions must be reported in amended filings. This material is...
Track Smith+Nephew and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Smith+Nephew and other trending companies.